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and the Reduced Derivative,
1,1,1-Trifluoro-2-chloroethane
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and Ronald K. Baker*
Halothane (1,1,1-trifluoro-2-bromo-2-chloroethane) is a safe, clinically useful inhalation anesthetic.
Rare, unpredictable cases ofliver necrosis have been reported following its use. Although the mechanism
of this reaction in man is unknown the most plausible is biotransformation to reactive intermediates
compounds. The oxidative metabolism of halothane appears to be benign. There is early evidence that
reductive (nonoxygen dependent) may be harmful. Since the bromine atom of halothane appears to
possess weak bond energy, the reduced, debrominated derivative of halothane, 1,1,1-trifluoro-
2-chloroethane, was synthesized and tested for hepatotoxicity in the rat. The derivative is unstable and
thus was prepared anaerobically and trapped in propylene glycol solvent. Injection of small amounts of
this compound into the portal vein ofrats produces extensive liver necrosis. It is postulated that biotrans-
formation ofhalothane via a reductive pathway could produce this reactive intermediate metabolite.
Introduction
The volatile anesthetic halothane (1,1,1-tri-
fluoro-2-bromo-chloroethane) was introduced into
clinical practice in the U.S. in 1958 and has sub-
sequently become the most commonly employed
drug of this category. There are many reasons to
endorse this popularity. It is easy to use, potent,
nonflammable, and possesses little in the way of
post-operative nausea or vomiting propensities.
The low blood/air partition coefficient (2.1) of the
anesthetic endows it with rapid induction charac-
teristics.
Soon after initial widespread clinical use, reports
appeared implicating halothane in the development
of post-anesthetic hepatic necrosis (1, 2). Although
such anecdotal case reports strongly implicated a
causal relationship, the rarity and unpredictability
of the syndrome was underlined by several large
prospective and retrospective studies which were
inconclusive. (3-5). Due to lack of animal models
*Department of Anesthesiology, University of Arizona Col-
lege of Medicine, Tucson, Arizona 85724.
tDepartments of Anesthesiology, Toxicology, and Phar-
macology, University of Arizona College of Medicine, Tucson,
Arizona 85724.
ofhalothane toxicity, a nonstatistical inference that
second administrations of the anesthetic increased
the incidence of hepatitis, and positive "challenge
tests" in susceptible individuals, it became vogue to
attribute the hepatic destruction to a peculiar al-
lergy or hypersensitivity limited to the human
species (6-8). It must be pointed out however that a
positive drug "challenge" only indicates that an in-
dividual is capable of an idiosyncratic reaction and
does not pinpoint mechanism of that reaction. In
addition the lymphocyte stimulation test, the only
concrete evidence upon which halothane hypersen-
sitivity theory was based has been disproven by
another group (9).
It was Van Dyke's and Stier's groups working
independently that determined that halothane was
extensively biotransformed by man and animals,
both in vivo and in vitro (10, 11). The primary
metabolic products formed were trifluoroacetic acid
and bromide. The mechanism is by an oxidative
reaction employing the classic NADPH-02 depen-
dent mixed function oxidase system. This oxidative
pathway is apparently innocuous and does not pro-
duce hepatic damage even in the presence of
phenobarbital induction. Later work has indicated
that nonoxygen-dependent ("reductive") biotrans-
formation may produce metabolites with sufficient
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pose ofthis article to investigate this possibility.
Methods
Since the bonding energy ofthe bromine atom in
halothane is relatively weak, it is theoretically pos-
sible that an enzymatic reductive attack could occur
at this site. Therefore the reduced, debrominated
produce of halothane, 1,1,1-trifluoro-2-chloro-
ethane, was synthesized and studied for hepato-
toxic potential.
Synthesis of 1,1,1-Trifluoro-2-chloroethane
The general reaction employed was:
trifluoroethanol (TFE) + PCl3
1,1,1-trifluoro-2-chloroethane + HCl
An airtight glassware apparatus was thoroughly
cleansed and dried overnight in an oven. The sys-
tem was set up and flushed for 30 min with pure N2.
An anaerobic sidearm buret containing PCl3 was
attached to the reaction flask which contained 5 ml
pure TFE. Then 10 ml saturated PCl3 was slowly
added to the TFE at ambient temperature and
stirred. The reaction was considered complete
when bubbling ceased. Two traps surrounded by a
Dry Ice/acetone mixture were placed distal to the
reaction flask. The first trap was to eliminate any
water condensate, and the second trap contained
anhydrous propylene glycol, 5 ml. By use of two
stopcocks, the effluent 1,1,1-trifluoro-2-chloro-
ethane was directed and dissolved into the propy-
lene glycol. This product was stable in this solvent
as long as it was stored in Dry Ice. Yield of this
reaction was approximately 1 g. Purity was greater
than 99%o determined by hydrolysis and chloride
gravimetry and by infrared spectroscopy. HCI was
eliminated by absorption and condensation.
Hepatotoxicity of
1,1,1-Trifluoro-2-chloroethane
This compound is extremely reactive, with a ten-
dency to explode on contact with water. Previous
data in man indicate that approximately 18% ofab-
sorbed halothane is biotransformed in man (10).
Extrapolation of these data to 250 g male
Sprague-Dawley rats means that approximately 6.5
mg of halothane would be metabolized in this
species primarily, it was assumed, by the oxidative
route. Therefore, ca. 1 mg of 1,1,1-trifluoro-
1-chloroethane in 0.5 ml propylene glycol was di-
rectly injected into the portal vein of rats under
pentobarbital anesthesia (25 mg/kg IP). After sutur-
ing the abdominal cavity the animals were placed in
acage with water and food adlibitum and sacrificed
24 hr later. After sacrifice, liver slices were taken,
fixed, stained with hematoxylin and eosin, and ex-
amined. Propylene glycol (0.5 ml) was used as con-
trol.
Results
Figure 1 illustrates the extensive coagulation ne-
crosis produced by injection of the 1,1,1-tri-
fluoro-2-chloroethane. All animals administered
this compound displayed this pattern. Propylene
glycol alone was innocuous.
Discussion
There is recent evidence from several groups of
investigators when placed in composite, indicating
that nonoxygen-dependent biotransformation of
halothane may be a potential vector ofhepatotoxic-
ity. Uehleke et al. (12) first indicated that covalent
binding of halothane metabolites to phenobarbital
pretreated rabbit hepatic microsomal protein was
enhanced if incubated in an anaerobic atmosphere.
It was speculated by this group that this irreversible
binding to endoplasmic reticulum proteins could be
connected with halothane hepatotoxic effects.
Wood et al. (13) also confirmed enhanced covalent
binding of halothane metabolites in an anaerobic
atmosphere, but found such binding higher in
microsomal phospholipids than in microsomal pro-
tein. In this last study, 36C1-halothane metabolites
had similar binding characteristics to
14C-halothane, strongly implying dechlorination did
not play a role in activation to reactive inter-
mediates. Cohen's group reported that halothane
was defluoridated to small amounts of
difluorobromo-chloroethane mercapturic acid in
man (14). Following this disclosure in man, Widger
et al. (15) found that there is enhanced defluorida-
tion of halothane in phenobarbital induced rats
anesthetized in a low (7%) oxygen atmosphere. As-
sociated with this metabolic alteration, these inves-
tigators found centrolobular necrosis ofthe liver.
In vivo evidence for the hepatotoxic potential of
induced halothane metabolism in the presence of
low oxygen tension has been confirmed by McLain
et al. (16). Anesthesia with 1% halothane in 14%
oxygen (85% N2) for 2 hr produces centrilobular
necrosis and rises in plasma SGOT and SGOT
within 24 hr in the rat. No evidence ofhepatotoxic-
ity is seen in phenobarbital pretreated control ani-
mals subjected to 85% N2 for a similar duration. In
addition, pretreatment of rats with high dosages of
the potent reductive enzyme inducing compound
Aroclor 1254 (a polychlorinated biphenyl) produces




FIGURE 1. Extensive necrosis ofthe liver 24 hrfollowing injection ofapproximately 2 mg 1,,1 I1-trifluoro-2-chloroethane in the portal
vein of a 250 g Sprague-Dawley rat.
centrilobular necrosis following halothane anes-
thesia, even in the presence of99% oxygen (17). In
no in vi'o studies has the possibility of an early
formation of 1,1,1-trifluoro-2-chloroethane been
critically investigated as yet.
Although the exact offending metabolite is un-
known, it is highly likely that "reductive" (non-
oxygen-dependent) biotransformation of halo-
thane can produce reactive intermediates of suf-
ficient reactivity to destroy liver cells. Reductive
debromination to 1,1,1-trifluoro-2-chloroethane is a
possible metabolite and has been found in this study
to be capable ofdestruction of liver morphology.
Summary
There is likelihood that reductive (nonoxygen-
dependent) biotransformation of halothane may
lead to reactive intermediates capable ofproducing
hepatotoxicity. One such intermediate which may
theoretically be formed by such a pathway is the
reduced, debrominated derivative of halothane,
1,1,1-trifluoro-2-chloroethane. This compound has
been synthesized and found to be quite reactive.
When appropriate amounts of this product are in-
jected into the portal veins of rats, extensive ne-
crosis ofthe liver results.
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